In this pre-clinical study, the efficacy of combining neratinib and dasatinib is investigated in HER2+ breast cancer models that (1) are naïve to therapy, (2) have acquired resistance to trastuzumab, and (3) are acquired neratinib-resistant. Here, ERBB2 is linked to breast cancer.